RxDoctor Payments Data

Veronica Holbrook, MD

Family Medicine · Pace, FLNPI 1821525114

Payments from drug & device makers

$477in general payments, 2019–2025

Across 20 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$184
  • Novo Nordisk$109
  • Dexcom, Inc.$43
  • GSK$33
  • Pfizer$32
  • Astellas Pharma US Inc$28
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$477100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie6$184
Novo Nordisk4$109
Dexcom, Inc.2$43
GSK2$33
Pfizer2$32
Astellas Pharma US Inc1$28
Medtronic1$17
Abbott1$17
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$477 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$26,592
Medicare patients
91
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide13$19,722
OzempicSemaglutide21$19,605
Arnuity ElliptaFluticasone Furoate11$3,501
Lidocaine12$2,776
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$1,606
Atorvastatin Calcium125$1,368
Potassium Chloride14$1,136
Memantine Hcl16$956
Levothyroxine Sodium78$819
Omeprazole36$663
Albuterol Sulfate HfaAlbuterol Sulfate29$575
Gabapentin19$563
Losartan Potassium58$548
Amlodipine Besylate64$395
Tamsulosin Hcl27$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$109$19,60521 claims
GSKArnuity Ellipta$33$3,50111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pace

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →